Feed aggregator
Holidaymakers warned about 'explosive diarrhoea' cyclospora parasite infection
'I want to break the stigma around herpes'
Is improved folate status in Northern Ireland a result of improved analytical performance or the implementation of folic acid fortification of flour legislation?
How to do neon festival make-up - without harming your skin
'It was heartbreaking to attend a fertility appointment in a maternity unit'
The Documentary Podcast
Inside Health
'Things need to change': The campaign for women's minister
'Things need to change': The campaign for women's minister
Meet the teenagers calling for action on violence against women and girls
Assignment
Hundreds of thousands of women get morning-after pill via free pharmacy service
UKAS welcomes the Pathology Transformation Review 2026
UKAS welcomes the Pathology Transformation Review, chaired by Lord Carter of Coles, and its recognition of the central role of accreditation and quality assurance in supporting safe, effective and resilient pathology services across the UK.
The report rightly highlights that accreditation coverage remains strong across pathology laboratories, while assurance must continue to evolve with new service models, technologies and testing pathways beyond traditional laboratories.
We welcome the report’s focus on strengthening quality governance through better alignment between UKAS, CQC, NHS bodies, commissioners and other stakeholders. Accreditation demonstrates competence, consistency and confidence, but works best alongside robust governance, transparent data, effective leadership and continual improvement. Recommendations on accountability, harmonised quality management, escalation and meaningful metrics provide a valuable basis for discussion.
The report also highlights the importance of assuring quality across point-of-care testing, digital pathology, genomics and direct-to-patient services. As diagnostic pathways become more distributed, assurance frameworks must support confidence in service quality wherever testing is delivered.
UKAS supports the report’s emphasis on proportionate, risk-based assurance and objective quality data to drive improvement, strengthen visibility of performance, support consistent standards and enable innovation while maintaining patient safety.
UKAS welcomes the report’s broader analysis of pathology challenges, including rising demand, workforce constraints, variable digital maturity and operational consistency. Its focus on resilience, training capacity, advanced practice roles, sustainable service models, interoperable systems and high-quality data reflects priorities fundamental to high-quality diagnostics.
UKAS also notes the report’s view of pathology as an end-to-end diagnostic pathway rather than solely a laboratory service. Recommendations on access, patient pathways, community diagnostics and emerging technologies are highly relevant as healthcare evolves. Maintaining confidence will require innovation and investment, alongside consistent governance, robust validation and effective assurance across care settings.
As pathology services transform, UKAS stands ready to engage with CQC, NHS leaders, professional bodies, government departments and other stakeholders to support effective, proportionate and sustainable quality assurance. Together, we can help ensure innovation, integration and service redesign deliver benefits while maintaining the quality and patient safety the public expects.
The post UKAS welcomes the Pathology Transformation Review 2026 appeared first on UKAS.
Badenoch says PM must rule out tax rises to fund social care reform
Burnham to address social care, youth unemployment and devolution
First person gets new experimental vaccine for Ebola
Female veterans support group makes national impact
'Evidence lacking' for mental health monitoring tech
Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types
BackgroundCirculating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing may help estimate recurrence risk after treatment. We performed a Bayesian secondary reanalysis of published aggregate data to estimate prognostic and diagnostic ...
Untargeted LC-MS/MS profiling identifies ST18 as a novel serum marker for T2DM-associated depression
Depression is a prevalent but underdiagnosed comorbidity in type 2 diabetes mellitus (T2DM), intensifying disease burden and complicating metabolic management. Reliable biomarkers for early detection remain limited. This study aimed to identify serum ...



